Assesment of JL1 Expression in Acute Leukemia
1 other identifier
interventional
50
0 countries
N/A
Brief Summary
The aim of this study is to assess JL1 expression by flow cytometric immunophenotyping in patients with B-cell Acute Lymphoblastic Leukemia (ALL) and to correlate it with clinical, morphological, immunophenotypic, cytogenetic data and response to treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started Oct 2020
Typical duration for phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 14, 2020
CompletedFirst Posted
Study publicly available on registry
September 18, 2020
CompletedStudy Start
First participant enrolled
October 13, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2023
CompletedSeptember 18, 2020
September 1, 2020
3 years
September 14, 2020
September 17, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluation and assessment of JL1 expression in B-cell Acute Lymphoblastic Leukemia.
Correlatin of this marker with clinical, morphological, immunophenotypic, cytogenetic data and response to treatment.
Baseline
Study Arms (2)
JL1
EXPERIMENTALJL1 on acute leukemia
JL1 and acute leukemia
EXPERIMENTALAssesment of JL1 expression on acute leukemia
Interventions
we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
Eligibility Criteria
You may qualify if:
- Patients with newly diagnosed B-cell ALL.
- Age group: both pediatric patients (\< 18 years old) and adult patients (\> 18 years old) will be included in our study.
You may not qualify if:
- \. Patients with other types of hematologic neoplasms. 2 .Relapsed patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53.
PMID: 28665419BACKGROUNDPark YS, Park SH, Park SJ, Kim Y, Jang KT, Ko YH, Lee MW, Huh JR, Park CS. Expression of JL1 is an effective adjunctive marker of leukemia cutis. Arch Pathol Lab Med. 2010 Jan;134(1):95-102. doi: 10.5858/2008-0699-OAR.1.
PMID: 20073611BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 14, 2020
First Posted
September 18, 2020
Study Start
October 13, 2020
Primary Completion
October 1, 2023
Study Completion
November 1, 2023
Last Updated
September 18, 2020
Record last verified: 2020-09